Copley will not reintroduce albuterol .5% solution following $150 mil. litigation settlement.
Executive Summary
COPLEY ALBUTEROL .5% SOLUTION WILL NOT BE REINTRODUCED, the company said following the announcement Aug. 22 of a $150 mil. settlement of litigation arising from its January 1994 Class I recall of the generic asthma product. The company previously had been projecting a reintroduction of the product by early 1996: in May, Copley Chairman Kenneth Larson told a Dillon, Read generic drugs conference that Copley planned to reintroduce the albuterol solution to the market in the next 12 months ("The Pink Sheet" May 22, T&G-17).
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth